8 recruiting, 3 active not recruiting, 2 completed, 2 withdrawn. 8 Phase 2, 4 Phase 1, 2 Phase 3, 1 Not applicable.
Follow ER Positive Breast Cancer: new trials by email Literature Review of ER Positive Breast Cancer trials Research Report on ER Positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Supporting Health Including Endocrine Treatment for Long Duration SHIELD portal - Breast Cancer, Breast Cancer - Female | Not applicable | Recruiting | Dana-Farber Cancer Institute | 30 | 2026-08-04 | 2026-08-10 |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Palazestrant, Letrozole-matching placebo, Ribociclib - Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Recruiting | Olema Pharmaceuticals, Inc. | 1000 | 2025-11-03 | 2026-09-23 |
| A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations ATV-1601, ATV-1601 + Fulvestrant - Advanced Solid Tumors, Breast Cancer | Phase 1 | Active not recruiting | Atavistik Bio, Inc | 134 | 2025-07-29 | 2026-08-07 |
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs Datopotamab Deruxtecan - Breast Cancer, Breast Cancer Female | Phase 2 | Recruiting | Nancy Lin, MD | 58 | 2024-01-08 | 2026-08-06 |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Palazestrant, Fulvestrant, Anastrozole - Breast Cancer, Advanced Breast Cancer | Phase 3 | Active not recruiting | Olema Pharmaceuticals, Inc. | 510 | 2023-11-16 | 2026-08-13 |
| Fulvestrant + Neratinib In Breast Cancer NERATINIB, FULVESTRANT - Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer | Phase 2 | Withdrawn | Massachusetts General Hospital | 2023-07-01 | 2023-08-01 | |
| Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer Alpelisib, Tamoxifen, Zotatifin - Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Completed | Jennifer Lee Caswell-Jin | 19 | 2023-03-20 | 2026-02-12 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC Goserelin, Fulvestrant, Capivasertib - Premenopausal Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | National Taiwan University Hospital | 42 | 2023-01-17 | 2024-06-10 |
| Role of the Immune Environment in Response to Therapy in Breast Cancer Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver. - Breast Cancer, ER Positive Breast Cancer | Recruiting | Abramson Cancer Center at Penn Medicine | 300 | 2022-10-03 | 2025-07-08 | |
| Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers Neratinib, Letrozole (L) or Anastrozole (A), Trastuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Recruiting | Ruth O'Regan | 30 | 2022-07-21 | 2026-09-03 |
| D4 Choline Breast PET/CT Imaging scan - HER2-negative Breast Cancer, ER Positive Breast Cancer | Completed | Imperial College London | 6 | 2022-02-24 | 2024-08-26 | |
| Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) Letrozole 2.5mg - Breast Cancer, ER Positive Breast Cancer | Phase 2 | Active not recruiting | Dartmouth-Hitchcock Medical Center | 178 | 2021-08-13 | 2026-05-28 |
| To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer Thymidine kinase activity - Metastatic Breast Cancer, ER Positive Breast Cancer | Recruiting | Fondazione Sandro Pitigliani | 150 | 2020-12-01 | 2026-09-14 | |
| Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer Infigratinib, Tamoxifen, Omnipaque 350 - Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Terminated | Jennifer Lee Caswell-Jin | 4 | 2020-10-13 | 2026-02-12 |
| AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer AUY922 - Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Texas Tech University Health Sciences Center, El Paso | 2011-07-01 | 2017-05-09 |
Breast Neoplasms (16) · Triple Negative Breast Neoplasms (4) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Breast Diseases (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Genital Neoplasms, Female (1) · Neoplasm, Residual (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1)
Skin Diseases (16) · Skin and Connective Tissue Diseases (16) · Breast Diseases (15) · Neoplasms (15) · Neoplasms by Site (15) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adnexal Diseases (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Fulvestrant (5) · Letrozole (4) · Anastrozole (2) · Tamoxifen (2) · neratinib (2) · 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide (1) · ALX148 (1) · Alpelisib (1) · Gonadotropin-Releasing Hormone (1) · Goserelin (1) · Infusion Pumps (1) · Iohexol (1) · Iopamidol (1) · Tomography, X-Ray Computed (1) · Trastuzumab (1)
Jennifer Lee Caswell-Jin (2) · Olema Pharmaceuticals, Inc. (2) · Abramson Cancer Center at Penn Medicine (1) · Atavistik Bio, Inc (1) · Dana-Farber Cancer Institute (1) · Dartmouth-Hitchcock Medical Center (1) · Fondazione Sandro Pitigliani (1) · Imperial College London (1) · Massachusetts General Hospital (1) · Nancy Lin, MD (1) · National Taiwan University Hospital (1) · QuantumLeap Healthcare Collaborative (1) · Ruth O'Regan (1) · Texas Tech University Health Sciences Center, El Paso (1)
United States (12) · France (3) · Italy (3) · Spain (3) · Taiwan (3) · United Kingdom (3) · Australia (2) · Austria (2) · Belgium (2) · Canada (2) · Czechia (2) · Germany (2) · Hong Kong (2) · Hungary (2) · Malaysia (2)
Aditya Bardia, MD,MPH (1) · Ann H Partridge, MD, MPH (1) · Jennifer Caswell-Jin (1) · Jennifer Lee Caswell-Jin (1) · Jennifer Zhang, MD (1) · Laura Kenny (1) · Luca Malorni (1) · Mary D Chamberlin, MD (1) · Nancy Lin, MD (1) · Paula R Pohlmann, MD, MSc, PhD (1) · Ruth O'Regan, MD (1) · Yen-Shen Lu, MD, PhD (1) · Zeina Nahleh, M.D. (1)
K08CA252457 (1)